Khan Nadeem, Husain Syed Arman, Husain Syed Iman, Khalaf Natalia, George Joggy, Raissi Farshad, Segura Ana Maria, Kar Biswajit, Bogaev Roberta C, Frazier O H
Center for Cardiac Support, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas 77030, USA.
Tex Heart Inst J. 2012;39(4):554-6.
We report the case of a patient who had chronic anthracycline-induced cardiomyopathy that was reversed after treatment with a left ventricular assist device. A 29-year-old woman had undergone anthracycline-based chemotherapy as a teenager in 1991 and 1992 and received a diagnosis of dilated cardiomyopathy 10 years later. Optimal medical therapy had initially controlled the symptoms of heart failure. However, in June 2006, the symptoms worsened to New York Heart Association functional class IV status. We implanted a continuous-flow left ventricular assist device as a bridge to cardiac transplantation; of note, a left ventricular core biopsy at that time showed no replacement fibrosis. The patient's clinical status improved thereafter, enabling left ventricular assist device ex-plantation after 17 months. To our knowledge, this is the first report of the use of left ventricular assist device support to reverse chronic anthracycline-induced heart failure.
我们报告了一例患有慢性蒽环类药物诱导的心肌病的患者，该患者在接受左心室辅助装置治疗后病情得到逆转。一名29岁女性在1991年和1992年青少年时期接受了基于蒽环类药物的化疗，10年后被诊断为扩张型心肌病。最佳药物治疗最初控制了心力衰竭症状。然而，2006年6月，症状恶化至纽约心脏协会心功能IV级。我们植入了一台连续流左心室辅助装置作为心脏移植的过渡；值得注意的是，当时的左心室心内膜活检未显示替代纤维化。此后患者的临床状况有所改善，17个月后左心室辅助装置得以移除。据我们所知，这是首例使用左心室辅助装置支持来逆转慢性蒽环类药物诱导的心力衰竭的报告。
